We are aware of current issues with the ONS login. Please clear your device history/cache/cookies before attempting to log in. Thank you for your patience as we address this issue.

Oncology Drug Reference Sheet: Tivozanib

By: Darcy Burbage, DNP, RN, AOCN®, CBCN®

Published In: Voice

Publication Date: 2021-08-24

Description

On March 10, 2021, the U.S. Food and Drug Administration approved tivozanib (Fotivda^®), an oral kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies

View Article @ voice.ons.org

ONS Drug Education

Short summaries of newly approved oncology-related therapies or drugs with new indications.

View All Drug Education

Oncology Drug Reference Sheet: Tivozanib

Description

ONS Drug Education

Related Topics